Cipla

1,509.50
+0.80
(0.05%)
Market Cap
1,21,923.50 Cr
EPS
65.29
PE Ratio
23.68
Dividend Yield
1.06 %
Industry
Healthcare
52 Week High
1,702.05
52 Week Low
1,335.00
PB Ratio
3.91
Debt to Equity
0.02
Add Ratio
hide

Investment Returns

In Long Term
In Short Term
1 Year
0.00%
2 Years
0.00%
3 Years
0.00%
4 Years
0.00%
5 Years
0.00%
Analyst Rating
- By Refinitiv from33 analysts
BUY
Analysts have suggested that investors can buy this stock
Buy
Buy+57.58 %
+57.58 %
Hold
Hold+24.24 %
+24.24 %
Sell
Sell+18.18 %
+18.18 %
Competitors
LTP
Market Cap (₹ Cr.)
P/E Ratio
Revenue (₹ Cr.)
YoY Revenue Growth %
Net Profit (₹ Cr.)
YoY Profit Growth %
RSI
1,674.60
#1 4,01,792.63
35.11
#1 52,041.20
12.06
#1 10,980
-18.99
49.60
6,905.50
1,83,319.33
83.20
9,360.00
0.89
2,117
23.05
67.24
1,509.50
#3 1,21,923.50
#4 23.68
#4 28,409.50
#9 7.12
#3 5,291
#2 30.28
52.75
3,358.00
1,13,649.98
58.56
11,317.00
11.59
2,054
10.91
59.08
1,291.20
1,07,759.82
19.45
33,741.20
12.36
5,725
21.14
49.51
1,003.55
1,00,980.61
21.53
22,573.80
13.82
3,977
-0.19
69.48
2,390.00
98,642.17
49.11
12,207.40
19.57
1,925
-10.91
49.97
1,963.10
89,653.89
27.22
22,192.10
#1 19.94
3,024
#1 112.49
47.26
35,475.00
75,381.90
53.31
6,409.15
10.80
1,417
27.83
71.69
1,161.80
67,477.53
#1 19.42
31,378.10
17.55
3,366
-0.50
55.14
Forecast
Actual
Growth Rate
Revenue Growth
7.12 %
Net Income Growth
27.33 %
Cash Flow Change
21.07 %
ROE
9.10 %
ROCE
2.32 %
EBITDA Margin (Avg.)
5.95 %

Quarterly Financial Results

Quarterly Financials
Mar 2015
Jun 2015
Sept 2015
Dec 2015
Mar 2016
Jun 2016
Sept 2016
Dec 2016
Mar 2017
Jun 2017
Sept 2017
Dec 2017
Mar 2018
Jun 2018
Sept 2018
Dec 2018
Mar 2019
Jun 2019
Sept 2019
Dec 2019
Mar 2020
Jun 2020
Sept 2020
Dec 2020
Mar 2021
Jun 2021
Sept 2021
Dec 2021
Mar 2022
Jun 2022
Sept 2022
Dec 2022
Mar 2023
Jun 2023
Sept 2023
Dec 2023
Mar 2024
Jun 2024
Sept 2024
Dec 2024
Mar 2025
Revenue
3,042
3,812
3,410
3,137
3,312
3,581
3,699
3,717
3,510
3,584
4,102
3,887
3,536
4,016
4,081
3,985
4,366
3,973
4,365
4,307
4,395
4,342
5,026
5,241
4,645
5,536
5,547
5,534
5,288
5,421
5,882
5,845
5,801
6,406
6,766
6,690
6,332
6,785
7,152
7,183
6,887
Expenses
2,585
2,784
2,669
2,688
3,138
3,039
3,070
2,970
3,076
2,879
3,278
3,095
3,219
3,213
3,310
3,300
3,443
3,084
3,486
3,613
3,743
3,297
3,862
3,938
3,810
4,283
4,294
4,248
4,568
4,232
4,526
4,403
4,748
4,835
4,944
5,051
4,847
4,978
5,165
5,084
5,192
EBITDA
457
1,028
741
450
174
543
629
748
434
705
824
792
317
803
771
685
923
889
879
694
652
1,045
1,164
1,303
835
1,253
1,253
1,286
720
1,190
1,356
1,442
1,053
1,571
1,821
1,639
1,484
1,807
1,986
2,099
1,695
Operating Profit %
13 %
26 %
21 %
12 %
4 %
15 %
16 %
17 %
12 %
16 %
18 %
19 %
8 %
16 %
16 %
16 %
19 %
21 %
18 %
15 %
13 %
23 %
22 %
24 %
17 %
22 %
22 %
22 %
13 %
20 %
21 %
23 %
16 %
23 %
25 %
22 %
20 %
25 %
26 %
27 %
21 %
Depreciation
136
149
158
177
270
204
229
258
632
213
302
522
285
241
282
293
510
268
283
278
346
269
265
248
285
261
253
248
290
254
299
272
346
239
290
233
288
247
272
280
309
Interest
43
64
64
31
48
32
35
59
33
28
42
9
35
35
44
44
45
52
46
46
53
46
39
48
28
30
38
21
18
18
26
32
34
16
26
30
18
18
15
15
14
Profit Before Tax
390
892
595
322
-82
401
444
514
-137
557
574
340
199
620
509
449
501
663
681
506
328
799
926
1,022
544
996
996
1,054
448
975
1,100
1,218
745
1,375
1,594
1,474
1,259
1,611
1,789
1,916
1,504
Tax
106
242
43
54
5
57
74
129
-74
132
139
-63
46
175
142
127
144
216
207
167
89
233
266
270
132
286
287
297
77
268
303
410
224
377
439
405
327
436
484
342
290
Net Profit
284
650
552
269
-87
344
370
385
-63
425
435
404
153
446
367
322
358
447
475
339
239
566
659
752
412
710
709
757
371
706
797
808
522
998
1,155
1,068
932
1,176
1,305
1,575
1,214
EPS in ₹
3.24
8.09
6.76
3.24
-1.16
4.22
4.41
4.66
-0.77
5.08
5.25
4.98
2.22
5.60
4.68
4.12
4.56
5.93
5.85
4.35
3.05
7.17
8.25
9.28
5.13
8.86
8.82
9.03
4.49
8.51
9.78
9.92
6.51
12.34
14.01
13.08
11.63
14.58
16.13
19.45
15.13

Balance Sheet

Balance Sheet
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Total Assets
15,718
21,128
21,037
22,861
23,963
23,663
25,152
27,101
29,463
32,718
37,387
Fixed Assets
6,830
9,369
9,492
9,950
9,608
9,683
9,516
9,683
9,161
9,607
10,006
Current Assets
7,591
8,841
8,736
10,814
12,427
11,706
13,210
14,711
16,805
19,392
23,249
Capital Work in Progress
581
2,061
1,683
981
676
825
969
766
1,093
1,153
1,566
Investments
390
758
973
1,259
2,554
1,471
2,710
2,551
3,662
5,449
7,933
Other Assets
7,917
8,940
8,889
10,670
11,125
11,684
11,957
14,101
15,547
16,509
17,882
Total Liabilities
15,718
21,128
21,037
22,861
23,963
23,663
25,152
27,101
29,463
32,718
37,387
Current Liabilities
3,881
7,776
3,374
3,832
3,772
4,393
4,591
4,913
5,110
5,246
5,484
Non Current Liabilities
854
1,486
4,682
4,447
4,848
3,212
1,975
1,071
640
670
614
Total Equity
10,982
11,866
12,982
14,582
15,344
16,057
18,586
21,117
23,714
26,802
31,289
Reserve & Surplus
10,629
11,356
12,383
14,068
14,851
15,602
18,165
20,680
23,246
26,545
31,032
Share Capital
161
161
161
161
161
161
161
161
161
162
162

Cash Flow

Cash Flow
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Net Cash Flow
389
312
-248
243
-345
234
141
-132
-97
-49
30
Investing Activities
-950
-4,533
-1,304
-834
-1,688
114
-2,374
-1,858
-2,376
-2,983
-3,682
Operating Activities
1,173
1,741
2,382
1,463
1,691
3,068
3,755
3,326
3,238
4,134
5,005
Financing Activities
165
3,104
-1,326
-386
-349
-2,949
-1,240
-1,600
-958
-1,200
-1,293

Dividend History

Dividends per share (FY)
Dividend yield (FY) %
Dividends per share (FY)
Dividend yield (FY) %
Annual Cash Flows 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Dividend Per Share (₹) 0.00 2 3 3 4 5 5 8.5 13 16
Dividend Yield (%) 0.00 0.37 0.57 0.71 0.49 0.49 0.56 0.57 0.9 1.06

Corporate Action

Record Date Corporate Action Information Announcement Day LTP at Annoucement LTP at Record Day
25 Jul 2025 QUARTERLY RESULT ANNOUNCEMENT Quarterly Result Announcement
NA
25 Jul 2025 1,515.95 1,508.55
16 Jul 2025 ANNUAL GENERAL MEETING Annual General Meeting
NA
16 Jul 2025 1,520.10 1,508.55
27 Jun 2025 DIVIDEND Dividend
₹ 3.00 /share
27 Jun 2025 1,520.10 1,502.75
27 Jun 2025 DIVIDEND Dividend
₹ 13.00 /share
27 Jun 2025 1,520.10 1,502.75
13 May 2025 QUARTERLY RESULT ANNOUNCEMENT Quarterly Result Announcement
NA
13 May 2025 1,384.70 1,520.10
28 Jan 2025 QUARTERLY RESULT ANNOUNCEMENT Quarterly Result Announcement
NA
28 Jan 2025 1,491.40 1,419.55
29 Oct 2024 QUARTERLY RESULT ANNOUNCEMENT Quarterly Result Announcement
NA
29 Oct 2024 1,663.55 1,477.55
20 Aug 2024 ANNUAL GENERAL MEETING Annual General Meeting
NA
20 Aug 2024 1,339.55 1,562.90
02 Aug 2024 DIVIDEND Dividend
₹ 13.00 /share
02 Aug 2024 1,339.55 1,528.80
21 Jul 2023 DIVIDEND Dividend
₹ 8.50 /share
21 Jul 2023 943.60 1,048.95
26 Aug 2022 ANNUAL GENERAL MEETING Annual General Meeting
NA
26 Aug 2022 974.05 1,020.80
10 Aug 2022 DIVIDEND Dividend
₹ 5.00 /share
08 Aug 2022 926.15 1,038.20
11 Aug 2021 DIVIDEND Dividend
₹ 5.00 /share
09 Aug 2021 904.10 910.25

Announcements

Announcement under Regulation 30 (LODR)-Newspaper Publication1 day ago
Board Meeting Intimation for Quarter Ended 30Th June 2025 Under SEBI Listing Regulations2 days ago
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation3 days ago
Announcement under Regulation 30 (LODR)-Allotment of ESOP / ESPS6 days ago
Announcement under Regulation 30 (LODR)-Newspaper PublicationJun 20, 2025
Business Responsibility and Sustainability Reporting (BRSR)Jun 19, 2025
Notice Of 89Th Annual General Meeting And Integrated Annual Report For FY 2024-25Jun 19, 2025
Reg. 34 (1) Annual Report.Jun 19, 2025
Announcement under Regulation 30 (LODR)-Newspaper PublicationJun 12, 2025
Announcement under Regulation 30 (LODR)-Allotment of ESOP / ESPSJun 07, 2025
Intimation Under Regulation 30 Read With Schedule III Of The SEBI (Listing Obligations And Disclosure Requirements) Regulations 2015Jun 06, 2025
Announcement under Regulation 30 (LODR)-Change in ManagementJun 01, 2025
USFDA Inspection At CompanyS Manufacturing Facility In Bommasandra Bengaluru IndiaMay 30, 2025
Compliances-Reg.24(A)-Annual Secretarial ComplianceMay 29, 2025
Announcement under Regulation 30 (LODR)-Updates on AcquisitionMay 29, 2025
Announcement under Regulation 30 (LODR)-AcquisitionMay 29, 2025
Announcement under Regulation 30 (LODR)-Allotment of ESOP / ESPSMay 26, 2025
Clarification - Intimation Under Regulation 30 Read With Schedule III Of The SEBI (Listing Obligations And Disclosure Requirements) Regulations 2015 Submitted On 13Th May 2025May 23, 2025
Announcement under Regulation 30 (LODR)-AcquisitionMay 19, 2025
Update On USFDA Inspection At Facility Of Sitec Labs Limited In Mahape Navi Mumbai IndiaMay 17, 2025
Announcement under Regulation 30 (LODR)-Earnings Call TranscriptMay 16, 2025
Announcement under Regulation 30 (LODR)-Newspaper PublicationMay 14, 2025
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - OutcomeMay 13, 2025
Announcement under Regulation 30 (LODR)-Investor PresentationMay 13, 2025
Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseMay 13, 2025
Intimation Under Regulation 30 Read With Schedule III Of The SEBI (Listing Obligations And Disclosure Requirements) Regulations 2015May 13, 2025
Board Meeting Outcome for Outcome Of Board MeetingMay 13, 2025
Announcement under Regulation 30 (LODR)-Appointment of Statutory Auditor/sMay 13, 2025
Appointment Of Cost Auditor Secretarial Auditor And Statutory AuditorsMay 13, 2025
Record Date For Payment Of Final Dividend For FY 2024-25May 13, 2025
Corporate Action-Board approves DividendMay 13, 2025
Financial Results And Declaration Of DividendMay 13, 2025
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationApr 30, 2025
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationApr 30, 2025
Format of the Initial Disclosure to be made by an entity identified as a Large Corporate : Annexure AApr 29, 2025
Intimation Under Regulation 30 Read With Schedule III Of The SEBI (Listing Obligations And Disclosure Requirements) Regulations 2015Apr 24, 2025
Update On USFDA Inspection At Manufacturing Facility Of Medispray In Kundaim Goa IndiaApr 17, 2025
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationApr 17, 2025
Announcement under Regulation 30 (LODR)-Allotment of ESOP / ESPSApr 17, 2025
Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018Apr 16, 2025
Intimation Under Regulation 30 Of The SEBI (Listing Obligations And Disclosure Requirements) Regulations 2015Apr 11, 2025
Board Meeting Intimation for Quarter And Year Ended 31St March 2025 Under SEBI Listing RegulationsApr 07, 2025
Announcement under Regulation 30 (LODR)-Allotment of ESOP / ESPSMar 19, 2025
USFDA Inspection At Analytical Testing Facility Of Sitec In Mahape Navi Mumbai IndiaFeb 20, 2025
Intimation Under Regulation 30 Of The SEBI (Listing Obligations And Disclosure Requirements) Regulations 2015Feb 20, 2025
Announcement under Regulation 30 (LODR)-Updates on AcquisitionFeb 18, 2025
Announcement under Regulation 30 (LODR)-Investor PresentationFeb 18, 2025
Announcement under Regulation 30 (LODR)-Allotment of ESOP / ESPSFeb 13, 2025
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationFeb 10, 2025
Update On USFDA Inspection At CompanyS Manufacturing Facility In Virgonagar Bengaluru IndiaFeb 08, 2025

Technical Indicators

RSI(14)
Neutral
52.75
ATR(14)
Less Volatile
24.25
STOCH(9,6)
Neutral
56.93
STOCH RSI(14)
Neutral
45.48
MACD(12,26)
Bullish
0.03
ADX(14)
Weak Trend
10.62
UO(9)
Bearish
48.59
ROC(12)
Uptrend And Accelerating
0.35
WillR(14)
Neutral
-53.13

Mutual Fund Holdings

Funding HouseCurrent Holding %1M Change1M Change %3M Change %Last 6M Trend
Kotak Large & Midcap Fund Direct-Growth
0.00%
-1600000
-0.96%
-0.93%
SBI ELSS Tax Saver Fund Direct-Growth
3.01%
1387230
0.45%
0.73%
Kotak Arbitrage Fund Direct-Growth
0.42%
960700
0.18%
0.25%
Parag Parikh Flexi Cap Fund Direct-Growth
1.25%
887725
0.00%
0.02%
Tata Balanced Advantage Fund Direct - Growth
0.29%
-874100
-1.35%
-1.25%
Tata Arbitrage Fund Direct - Growth
0.89%
848400
0.82%
0.80%
Edelweiss Arbitrage Fund Direct-Growth
0.72%
599300
0.56%
0.51%
Kotak Flexicap Fund Direct-Growth
1.00%
-500000
-0.25%
-0.20%
Kotak ELSS Tax Saver Fund Direct-Growth
0.00%
-450000
-1.15%
-1.11%
SBI Quant Fund Direct-Growth
0.00%
-412740
-1.73%
-0.21%
HDFC Manufacturing Fund Direct - Growth
2.97%
-400000
-0.80%
-0.57%
Kotak Manufacture in India Fund Direct - Growth
0.00%
-320000
-2.15%
-2.04%
HDFC Flexi Cap Direct Plan-Growth
3.87%
300000
-0.25%
-0.11%
Tata Multi Asset Allocation Fund Direct - Growth
0.00%
-278200
-1.17%
-1.13%
HDFC Balanced Advantage Fund Direct-Growth
0.21%
-277225
-0.06%
-0.04%
HDFC Arbitrage Fund Wholesale Direct-Growth
0.72%
-251875
-0.28%
-0.06%
ICICI Prudential Equity Arbitrage Direct-Growth
0.52%
-225600
-0.19%
-0.25%
HDFC Focused Fund Direct-Growth
3.74%
200000
-0.27%
-0.03%
Axis ELSS Tax Saver Direct Plan-Growth
0.66%
-155068
-0.12%
-0.18%
DSP Top 100 Equity Direct Plan-Growth
3.87%
139826
-0.15%
-0.27%
Mirae Asset Healthcare Fund Direct - Growth
6.23%
-135000
-1.16%
-0.68%
Nippon India Arbitrage Fund Direct-Growth
0.28%
92950
0.08%
0.10%
Invesco India Arbitrage Fund Direct-Growth
0.08%
-87425
-0.08%
-0.29%
Canara Robeco Large and Mid Cap Fund Direct-Growth
0.00%
-79714
-0.05%
-0.21%
LIC MF ELSS Tax Saver Direct - Growth
0.98%
74715
0.98%
0.98%

About Cipla

Cipla Ltd is a leading Indian pharmaceutical company that manufactures, develops, and markets a wide range of branded and generic formulations and Active Pharmaceutical Ingredients (APIs). The company operates in two segments: Pharmaceuticals and New ventures. Its product portfolio includes complex generics and drugs in respiratory, anti-retroviral, urology, cardiology, anti-infective, and CNS therapeutic areas. Cipla has a global presence with manufacturing facilities and operations in India and international markets, including the United States, South Africa, and other countries. The company focuses on developing and producing generic and branded generic medicines, as well as expanding into consumer healthcare, biosimilars, and specialty business through its New ventures segment.
Chairperson NameY K Hamied